MASLD care: how Chinese physicians diagnose and manage liver disease
Official title: Attitudes, Perceptions, Clinical Practice, and Barriers in Diagnosis and Management of Patients With Metabolic Dysfunction-associated Steatotic Liver Disease: a Cross-sectional Survey on Physicians in China
Run by Novo Nordisk A/S · NCT07682363 · Data updated 2026-11-12
This survey asks Chinese doctors in major hospitals how they diagnose, assess fibrosis, and manage MASLD in patients with liver disease.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 470 (estimated) |
| Sponsor | Novo Nordisk A/S Industry-sponsored |
| Locations | 1 site (Beijing) |
| Status | Recruiting |
| Started | June 3, 2026 |
| Main results expected | February 23, 2027 |
| Study ends | February 23, 2027 |
| Registry record updated | July 2, 2026 |
| Trial ID | NCT07682363 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Physicians licensed to practice, with associate chief or senior attending status, who work in endocrinology, hepatology, infection, or gastroenterology, conduct outpatient clinics, and manage MASLD/MASH patients in Grade IIIA hospitals in provincial capitals or municipalities.
✕Probably not a fit
Participants may not receive personal benefit; the study only collects professional practices and opinions.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a cross-sectional survey of physicians across endocrinology, hepatology, infection, and gastroenterology in Grade IIIA hospitals in provincial capitals or municipalities. It collects attitudes, perceptions, and current clinical practices following MASLD diagnosis, focusing on fibrosis assessment and management strategies. No interventions or treatments are given; the study analyzes responses from clinicians to understand real-world patterns. Participation requires informed consent and meeting specific clinical and practice criteria. The study is sponsored by Novo Nordisk A/S with the Beijing investigational site as the location.
Why it matters
Potential benefit: The findings could inform how MASLD is managed in Chinese hospitals and identify gaps between guidelines and practice.
How similar studies have gone: Similar cross-sectional surveys have helped map physician practices in MASLD care in other regions, supporting the value of this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Has provided informed consent. * Registered clinical practice location in provincial capital or municipality. * Physician with a license for clinical practice. * Employed in the Department of Endocrinology, Hepatology, Infection or Gastroenterology. * Hospital level: Grade IIIA hospital. * Hold a professional title of associate chief physician or above, or senior attending physician (as an attending physician for more than or equal to (≥) 3 years). * Conducts outpatient clinics for at least 1 half-days per week. * The patient load of MASLD/MASH per month in the department should be: * a. Endocrinology ≥20 patients per month * b. Hepatology/Gastroenterology/ Infectious ≥30 patients per month Exclusion Criteria: -Participants will be excluded if they have unwillingness precluding adequate cooperation, fail to complete the questionnaire, or submit questionnaires verified as invalid.
Where it's running
-
Novo Nordisk Investigational site
Beijing, China Recruiting
Study contacts
- Study coordinator: Novo Nordisk
- Email: clinicaltrials@novonordisk.com
- Phone: (+1) 866-867-7178
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Referral to alcohol treatment for patients with liver disease
This study tests whether sending newly diagnosed patients with alcohol-related liver disease to specialized treatment can help them stop drinking better than just regular care alone.
-
Using fecal microbiota transplantation to treat gut disorders
This study is testing whether a treatment that involves using healthy stool to help restore gut bacteria can improve symptoms for people with gut disorders like Crohn's disease and irritable bowel syndrome.
-
Evaluation of patients with liver disease
This study is trying to learn more about liver diseases by checking in on patients with conditions like hepatitis B, C, and D through regular tests and follow-ups.
-
Additive Physical Activity for Hypothyroidism in Older Women with Glaucoma and Fatty Liver
We’re testing whether adding a treadmill-based exercise program to standard thyroid treatment helps improve health in older women who have subclinical hypothyroidism, glaucoma, and fatty liver.
-
Lowering insulin to reduce liver fat production
This study will try a short course of diazoxide to lower insulin and see if it reduces the liver's creation of new fat in adults with obesity, insulin resistance, and MASLD.
-
Efimosfermin alfa for adults with liver impairment
This trial will test a single dose of efimosfermin alfa in adults with cirrhosis-related hepatic impairment from steatotic liver disease, with and without significant alcohol use, to measure drug levels and safety.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.